Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1983 Oct;58(10):810–813. doi: 10.1136/adc.58.10.810

Effect of low dose 1 alpha-hydroxycholecalciferol on glomerular filtration rate in moderate renal failure.

F U Eke, M H Winterborn
PMCID: PMC1628291  PMID: 6357106

Abstract

Serial measurements of 51Cr edetic acid clearance were made over a period of one year in two groups of 8 children, in a double blind trial of 1 alpha-hydroxycholecalciferol (10 ng/kg/day) and calciferol (670 ng/kg/day). Glomerular filtration rate (GFR) at the beginning of the trial was 20-50 ml/min/1.73 m2; it rose in the children given 1 alpha-hydroxycholecalciferol (group A) after 6 months but was not appreciably different from the pretreatment value after 12 months. The GFR in the children given calciferol (group B) showed no significant difference at 6 or 12 months. Parathyroid hormone values fell markedly in group A after 6 months but not in group B. Quantitative bone histology improved considerably in group A but not in group B at 12 months. Low dose 1 alpha-hydroxycholecalciferol may be used effectively for renal osteodystrophy in children with moderate but stable renal failure without jeopardising renal function.

Full text

PDF
810

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brancaccio D., Galmozzi C., Casati S., Ponticelli C. Propranolol in uraemic osteodystrophy. Lancet. 1978 Oct 28;2(8096):940–940. doi: 10.1016/s0140-6736(78)91653-7. [DOI] [PubMed] [Google Scholar]
  2. Brickman A. S., Coburn J. W., Friedman G. R., Okamura W. H., Massry S. G., Norman A. W. Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man. J Clin Invest. 1976 Jun;57(6):1540–1547. doi: 10.1172/JCI108424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Canterbury J. M., Lerman S., Claflin A. J., Henry H., Norman A., Reiss E. Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog. J Clin Invest. 1978 May;61(5):1375–1383. doi: 10.1172/JCI109055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Caro J. F., Besarab A., Burke J. F., Glennon J. A. A possible role for propranolol in the treatment of renal osteodystrophy. Lancet. 1978 Aug 26;2(8087):451–454. doi: 10.1016/s0140-6736(78)91447-2. [DOI] [PubMed] [Google Scholar]
  5. Charbon G. A., Hulstaert P. F. Augmentation of arterial hepatic and renal flow by extracted and synthetic parathyroid hormone. Endocrinology. 1974 Aug;95(2):621–626. doi: 10.1210/endo-95-2-621. [DOI] [PubMed] [Google Scholar]
  6. Farrington K., VArghese Z., Moorhead J. F. Vitamin-D analogues and renal function. Lancet. 1978 Oct 28;2(8096):941–941. doi: 10.1016/s0140-6736(78)91656-2. [DOI] [PubMed] [Google Scholar]
  7. Fournier A., Sebert J. L., Coevoet B., De Fremont J. F., Hardin J. M., Lambrey G. Current status of the management of renal osteodystrophy. Proc Eur Dial Transplant Assoc. 1978;15:547–568. [PubMed] [Google Scholar]
  8. Impairment of renal function in patients on 1alpha-hydroxycholecalciferol. Lancet. 1978 Aug 19;2(8086):427–428. [PubMed] [Google Scholar]
  9. Kanis J. A., Henderson R. G., Heynen G., Ledingham J. G., Russell R. G., Smith R., Walton R. J. Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol. Arch Dis Child. 1977 Jun;52(6):473–481. doi: 10.1136/adc.52.6.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Malluche H. H., Massry S. G. The role of vitamin D metabolites in the management of bone abnormalities in renal disease. Adv Exp Med Biol. 1980;128:615–624. doi: 10.1007/978-1-4615-9167-2_63. [DOI] [PubMed] [Google Scholar]
  11. Malluche H. H., Ritz E., Lange H. P., Kutschera L., Hodgson M., Seiffert U., Schoeppe W. Bone histology in incipient and advanced renal failure. Kidney Int. 1976 Apr;9(4):355–362. doi: 10.1038/ki.1976.42. [DOI] [PubMed] [Google Scholar]
  12. Naik R. B., Cundy T., Robinson B. H., Russell R. G., Kanis J. A. Effects of vitamin D metabolites and analogues on renal function. Nephron. 1981;28(1):17–25. doi: 10.1159/000182088. [DOI] [PubMed] [Google Scholar]
  13. Nielsen H. E., Rømer F. K., Melsen F., Christensen M. S., Hansen H. E. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function. Clin Nephrol. 1980 Mar;13(3):103–108. [PubMed] [Google Scholar]
  14. Pierides A. M., Ellis H. A., Ward M. K., Simpson W., Kerr D. N. 1alpha-Hydroxycholecalciferol in renal osteodystrophy. Calcif Tissue Res. 1977 May;22 (Suppl):105–111. doi: 10.1007/BF02064049. [DOI] [PubMed] [Google Scholar]
  15. Tougaard L., Sorensen E., Brochner-Mortensen J., Christensen M. S., Rodbro P., Sorensen A. W. Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure. Lancet. 1976 May 15;1(7968):1044–1047. doi: 10.1016/s0140-6736(76)92220-0. [DOI] [PubMed] [Google Scholar]
  16. Winterborn M. H., Mace P. J., Heath D. A., White R. H. Impairment of renal function in patients on 1alpha-hydroxycholecalciferol. Lancet. 1978 Jul 15;2(8081):150–151. doi: 10.1016/s0140-6736(78)91530-1. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES